• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

myrbetriq

  1. Myrbetriq Sales

    Been out a while. Has Myrbetriq hit the number #1 prescribed OAB agent? Or Has the fact Vesicare is going generic stopped that? What about the fact a combo drug with those two will have crap coverage? How are the feeling of the sales force?
  2. Is the ship really sinking?

    Just curious to the state of Astellas? How morale? I heard Vesicare is going generic 2018/2019.